Showing 4 posts of 4 posts found.


NICE approves Imbruvica for second-line leukaemia treatment

January 26, 2017
Medical Communications, Sales and Marketing AbbVie, CLL, Janssen, ibrutinib, imbruvica

NICE has issued its Technology Appraisal Guidance (TAG) that has recommend Imbruvica (ibrutinib) for the treatment of chronic lymphocytic leukaemia …


Lowered price wins NICE approval for Janssen leukaemia treatment

November 25, 2016
Medical Communications, Sales and Marketing Janssen, NICE, SMC, chronic lymphocytic leukaemia, ibrutinib, imbruvica

After being knocked back in the beginning of June this year, NICE has announced that Janssen’s Imbruvica (ibrutinib) will now …

J&J image

J&J strong pharma sales can’t offset Q1 losses

April 15, 2015
Sales and Marketing J&J, JJ, Q1, Waldenström's macroglobulinemia, Waldenström’s Macroglobulinemia, Zytiga, abiraterone acetate, financials, ibrutinib, imbruvica

Johnson & Johnson’s pharma division achieved worldwide sales of $7.7 billion in the first quarter of this year – but …

Amgen image

Amgen’s colorectal cancer drug EU approved

April 8, 2015
Sales and Marketing Amgen, Vectibix, ibrutinib, imbruvica, panitumumab, ristempa

The European Commission has shown Amgen’s cancer drug Vectibix the green light to treat patients in combination with chemotherapy for …

Latest content